New Hampshire 2026 Session Status: Passed House Bipartisan · 3 D · 2 R cosponsors

HB 1809 — establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

Last action — Inexpedient to Legislate, MA, VV === BILL KILLED ===; 05/07/2026; SJ 11

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill has passed the House. Introduced December 18, 2025. It now moves to the second chamber.

Next likely step: consideration and a floor vote in the Senate.

Odds of enactment

High chance

Based on the sponsor, cosponsors, and committee posture, this bill has a high chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 54% · moderate confidence

  • Passed House

    Current position in the legislative process.

  • 6 sponsors

    1 primary, 5 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (3 D · 2 R) — cross-party backing.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

(New Title) establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

Bill Text

What changed in the latest version

86 added · 121 removed

Plain-language change summary

The recent amendments to Bill HB 1809 change its focus from simply authorizing the medical use of psilocybin to establishing a dedicated advisory board to study its therapeutic benefits and drawbacks. This shift is significant as it emphasizes a structured approach to evaluating psilocybin's potential within a monitored environment, ensuring that any medical applications are carefully considered and regulated. Overall, the revised bill aims to ensure that the use of psilocybin in therapy is both safe and effective while involving expert oversight.

→
Previous
Latest
HB 1809-FN - AS INTRODUCED SESSION 26-2497 05/09 HOUSE BILL 1809-FN AN ACT authorizing the medical use of psilocybin through a program established in the department of health and human services.
HB 1809-FN - AS AMENDED BY THE HOUSE 26Mar2026...
1201h SESSION 26-2497 05/09 HOUSE BILL 1809-FN AN ACT establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.
Health, Human Services and Elderly Affairs ───────────────────────────────────────────────────────────────── ANALYSIS This bill authorizes the medical use of psilocybin through a program established in the department of health and human services.
Health, Human Services and Elderly Affairs ───────────────────────────────────────────────────────────────── AMENDED ANALYSIS This bill establishes a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.
HB 1809-FN - AS INTRODUCED 26-2497 05/09 STATE OF NEW HAMPSHIRE In the Year of Our Lord Two Thousand Twenty-Six AN ACT authorizing the medical use of psilocybin through a program established in the department of health and human services.
HB 1809-FN - AS AMENDED BY THE HOUSE 26Mar2026...
1201h 26-2497 05/09 STATE OF NEW HAMPSHIRE In the Year of Our Lord Two Thousand Twenty-Six AN ACT establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.
The purpose of this act is to create a carefully monitored and closely supervised setting in which an approved medical provider can treat a carefully chosen patient with appropriate doses of psilocybin which that same provider has produced for a medical intervention.
The purpose of this act is to study the feasibility of the creation of a carefully monitored and closely supervised setting in which an approved medical provider can treat a carefully chosen patient with appropriate doses of psilocybin which that same provider has produced for a medical intervention.
Medical Use of Psilocybin.
Medical Psilocybin Advisory Board.
Amend RSA by inserting after chapter 126-Z the following new chapter:
Amend RSA by inserting after chapter 126- Z the following new chapter:
CHAPTER 126-ZZ MEDICAL USE OF PSILOCYBIN 126-ZZ:1 Definitions.
CHAPTER 126-ZZ Medical Psilocybin Advisory Board 126-ZZ:1 Definitions.
“Provider” means an approved medical provider licensed in New Hampshire who has been approved by the department to provide medical services to qualified patients and who has been approved by the department to produce the psilocybin they will use as a provider.
“Provider” means an approved medical provider licensed in New Hampshire who has been approved by the department to provide medical services to qualified patients.
“Medical services” means services provided to a patient in an approved setting before, during, and after the ingestion of psilocybin and includes a preparation session, an administration session and an integration session.
“Producer" means a person who grows and harvests or prepares psilocybin from psilocybin-producing mushrooms, including to compound, convert, process, or manufacture psilocybin products directly or indirectly from psilocybin mushrooms and who has been approved as a provider.
“Provider" or "producer" means a person who grows and harvests or prepares psilocybin from psilocybin-producing mushrooms, including to compound, convert, process, or manufacture psilocybin products directly or indirectly from psilocybin mushrooms and who has been approved as a provider.
V.
VI.
V.
HB 1809-FN - AS INTRODUCED - Page 2 - VII.
VI.
“Qualified patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, IV, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition.
“Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition.
VIII.
VII.
“Qualifying condition” includes:
“Qualifying condition” means any of the following:
(a) Major treatment-resistant depression;
HB 1809-FN - AS AMENDED BY THE HOUSE - Page 2 - (a) Major treatment-resistant depression;
and (d) Other conditions recommended by the advisory board to the department and approved by the department.
and (d) Other conditions recommended by the advisory board to the department.
126-ZZ:2 Medical Use of Psilocybin Program.
126-ZZ:2 Medical Psilocybin Advisory Board.
The department shall establish a medical use of psilocybin program that will:
Approve providers for the use of psilocybin in therapeutic doses with qualifying patients.
There is hereby established the medical psilocybin advisory board, which shall assess the clinical, quality, and public health related advantages and disadvantages of the use of psilocybin for therapeutic purposes under this chapter and, if appropriate, design a program for the medical use of psilocybin.
Approve the above providers as producers of psilocybin in therapeutic doses to qualifying patients.
Notwithstanding RSA 14:49, the board shall consist of the following members:
III.
(a) The medical director of the department of health and human services, or designee.
Compile a public list of provider/producers that includes the name and address of each provider and provider/producer.
(b) A qualifying patient, appointed by the commissioner of the department of health and human services.
IV.
(c) A representative from the veterans’ affairs community, appointed by the commissioner of the department of health and human services.
Establish requirements for data collection to evaluate the program and the use of best practices by provider/producers.
(d) A representative from the house of representatives, appointed by the speaker of the house of representatives.
V.
(e) A representative from the house of representatives, nominated by the minority leader of the house and appointed by the speaker of the house of representatives.
Establish other requirements, restrictions, and limitations through rules promulgated by the department to ensure an efficacious program.  126-ZZ:3 Provider/Producer Application.
(f) Nine medical and other providers, appointed by the commissioner of the department of health and human services, representing the following fields:
Only a provider/producer who has received an approval by the department for the medical use of psilocybin subject to the rules established under 126-ZZ:4 shall be allowed to provide psilocybin to a qualified patient.
To receive an approval, the provider shall complete an application that:
I.
Lists the names, addresses, and birthdates of the owner of the provider’s organization or business and all those within the organization or business who will be involved in any fashion with the medical use of psilocybin.
II.
Provides the curriculum vitae of all those within the organization or business who will supervise the use of psilocybin by a qualified patient.
III.
Identifies and describes the location or locations at which the supervised medical use of psilocybin will occur.
IV.
Identifies and describes the location or locations at which the supervised production of psilocybin will occur.
Show all 79 changed rows (39 more)
Previous
Latest
V.
Identifies any other state in which the provider/producer has been authorized in any fashion to provide psilocybin medically or therapeutically.
126-ZZ:4 Rulemaking;
Approval of Provider/Producers.
The commissioner of the department of health and human services shall adopt rules under RSA 541-A in consultation with the medical HB 1809-FN - AS INTRODUCED - Page 3 - psilocybin advisory board relative to administration of the psilocybin program, including eligibility criteria for patients, application procedures, and criteria for approval of provider/producers.
126-ZZ:5 Exemptions.
A provider/producer who produces therapeutic amounts of psilocybin and provides a qualifying patient with therapeutic amounts of psilocybin shall be exempt from state criminal statutes regarding the possession, production, or sale of those therapeutic amounts provided to qualifying patients.
Any provider/producer who produces psilocybin for any use other than for providing therapeutic doses to a qualifying patient shall not be exempt from criminal prosecution.
Any provider/producer who provides psilocybin to anyone for any use other than to provide therapeutic doses to a qualifying patient shall not be exempt from criminal prosecution.
126-ZZ:6 Advisory Board.
I.
There is hereby established the medical psilocybin advisory board which shall monitor and contribute to the assessment of the clinical, quality, and public health related matters of the use of psilocybin for therapeutic purposes under this chapter.
II.
The board shall consist of the following members:
(a) The medical director, department of health and human services, or designee;
(b) A qualifying patient, appointed by the commissioner of the department;
(c) A representative from the veterans’ affairs community;
(d) Eight medical and other providers, appointed by the commissioner, representative of the following fields:
The members of the board need not be residents of New Hampshire in order to encourage the greatest possible expertise in board members.
The board shall convene at least 6 times per year to assess the clinical, quality, and public health related advantages and disadvantages of the use of psilocybin for therapeutic purposes under this chapter and, if appropriate, design a program for the medical use of psilocybin by:
IV.
At its first meeting the board shall elect by majority vote a chairperson and an alternate.
A quorum shall consist of a majority of members.
V.
The board shall convene at least 4 times per year to monitor and contribute to the oversight and assessment of the clinical, quality, and public health related matters of therapeutic psilocybin under this chapter by:
HB 1809-FN - AS INTRODUCED - Page 4 - (b) Monitoring clinical outcomes.
(b) Identifying clinical outcomes nationally.
(c) Reviewing protocols for producer/provider staff based on models from other states.
HB 1809-FN - AS AMENDED BY THE HOUSE - Page 3 - (c) Reviewing potential protocols for producer/provider staff based on models from other states.
(f) Reviewing any other clinical, quality, and public health related matter relative to use of psilocybin under this chapter.
(f) Reviewing any other clinical, quality, and public health related matter relative to use of psilocybin.
(g) Reviewing the efficacy of a further expansion of the therapeutic psilocybin program.
(g) Reviewing the efficacy of the establishment of therapeutic psilocybin program in New Hampshire.
IV.
The members of the board need not be residents of New Hampshire in order to encourage the greatest possible expertise in board members.
V.
At its first meeting, the board shall elect by majority vote a chairperson and an alternate.
The board shall be empowered to meet electronically to facilitate the inclusion of members who live outside the state of New Hampshire.
The board may meet electronically to facilitate the inclusion of members who live outside the state of New Hampshire.
Beginning January 1, 2027, and annually thereafter, the board shall submit a report of its activities, findings, and recommendations to the governor, speaker of the house of representatives, senate president, house clerk, senate clerk, and state library.
Beginning November 1, 2028, and annually thereafter, the board shall submit a report of its activities, findings, and recommendations to the governor, speaker of the house of representatives, senate president, house clerk, senate clerk, and state library.
3 Contingency.
3 Repeal.
RSA 126-ZZ:1 through RSA 126-ZZ:5, as inserted by section 2 of this act, shall take effect 30 days after the medical psilocybin advisory board certifies to the governor, speaker of the house of representatives, the president of the senate, and the director of the office of legislative services that the program is ready for implementation as outlined in RSA 126-ZZ.
RSA 126-ZZ, relative to the medical psilocybin advisory board, is repealed.
If the medical psilocybin advisory board does not make such a certification within 2 years of the effective date of this act, RSA 126-ZZ:1 through RSA 126-ZZ:5 shall not take effect.
RSA 126-ZZ:1 through RSA 126-ZZ:5, as inserted by section 2 of this act, shall take effect as provided in section 3 of this act.
Section 3 of this act shall take effect November 1, 2030.
The remainder of this act shall take effect upon its passage.
The remainder of this act shall take effect July 1, 2027.
⬇ Download PDF
View plain text versions (2)

Action History

  1. Inexpedient to Legislate, MA, VV === BILL KILLED ===; 05/07/2026; SJ 11

  2. Committee Report: Inexpedient to Legislate, 05/07/2026, Vote 4-0, CC; SC 17

  3. Hearing: 04/08/2026, Room 100, SH, 09:45 am; SC 13

  4. Introduced 03/26/2026 and Referred to Health and Human Services; SJ 7

  5. Ought to Pass with Amendment 2026-1201h: MA VV 03/26/2026 HJ 9 P. 43

  6. Amendment # 2026-1201h (NT): AA DV 248-101 03/26/2026 HJ 9 P. 42

  7. Inexpedient to Legislate: MF DV 127-222 03/26/2026 HJ 9 P. 42

  8. Minority Committee Report: Ought to Pass with Amendment # 2026-1201h (NT)

  9. Majority Committee Report: Inexpedient to Legislate 03/17/2026 (Vote 13-11; RC)

  10. Executive Session: 03/17/2026 10:00 am GP 230

  11. Division III Work Session: 03/13/2026 09:00 am GP 234

  12. Referred to Finance 02/12/2026 HJ 4 P. 7

  13. Ought to Pass: MA VV 02/12/2026 HJ 4 P. 7

  14. Committee Report: Ought to Pass 01/28/2026 (Vote 18-0; CC) HC 6 P. 7

  15. Executive Session: 01/28/2026 02:30 pm GP 158

  16. Public Hearing: 01/14/2026 03:00 pm GP 158

  17. Introduced 01/07/2026 and referred to Health, Human Services and Elderly Affairs HJ 1 P. 37

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 5 co-sponsors · 409 not signed on

Sponsors (1)

Co-sponsors (5)

Not signed on (409)

409 members have not signed on to this bill.

Show all 409 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 1809 do?
(New Title) establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.
Who sponsors HB 1809?
HB 1809 is sponsored by Matt R Sabourin dit Choinière, Buzz Scherr (Democrat), Jennifer Mandelbaum (Democrat), Donovan Fenton (Democrat), Carol McGuire (Republican), and Erica Layon (Republican).
What is the current status of HB 1809?
This bill has passed the House. Introduced December 18, 2025. It now moves to the second chamber.
Where can I track HB 1809?
Track HB 1809 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 1809

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 1809

Last checked for changes about 1 month ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →